FIELD: chemistry.
SUBSTANCE: invention relates to a compound represented by following general formula (I) or a pharmaceutically acceptable salt thereof, where A is -(CH2)n-X-, -(CH2)m-NH- or -(C3-C7 cycloalkylene)-NH-; n is an integer from 0 to 2; m is an integer from 1 to 4; X is a nitrogen-containing C3-C5 heterocycloalkylene; Y represents C(R4)=C(R5)(R6) or -C≡C-R7; W and Z each independently represent N or CH; R1 is an amino group; one of R2 and R3 represents a hydrogen atom or C1-C6 alkyl group, while the second of R2 and R3 represents a hydrogen atom, a halogen atom, C1-C6 alkyl group, halogen-C1-C6 alkyl group, C1-C6 alkoxy-substituted C1-C6 alkyl group, C1-C6 alkoxy group, a phenyl group which may contain one or more substituents selected from a halogen atom, 4-6 membered monocyclic unsaturated heterocyclic group containing 1 sulfur heteroatom, or a cyano group; if Y is -C(R4)=C(R5)(R6), each of R4, R5, R6 and R7, which may be the same or different, represents a hydrogen atom or C1-C6 alkyl group which may be substituted with an amino group substituted with two C1-C6 alkyl groups (C1-C6 alkyl groups can form a 4-8 membered heterocycloalkyl group together with the nitrogen atom to which they are attached); and if Y is -C≡C-R7, R7 is a nitrogen atom or C1-C6 alkyl group. Compound of formula (I) also represents a probe compound for the detection of BTK. 
.
EFFECT: compounds of formula (I) have an inhibitory effect on Bruton’s tyrosine kinase (BTK) and are intended for the treatment of tumors.
16 cl, 1 dwg, 52 tbl, 93 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR PREVENTING AND/OR TREATING IMMUNE DISEASE | 2016 |
|
RU2705154C2 |
| AMINOPYRAZOLOPYRIMIDINE COMPOUND USED AS INHIBITOR OF TYROSINE KINASE RECEPTOR OF NEUROTROPHIC FACTOR | 2017 |
|
RU2764523C2 |
| PYRAZOLOPYRIMIDINES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | 1993 |
|
RU2124016C1 |
| SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK, THEIR PREPARATION AND USE IN TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASES | 2014 |
|
RU2677884C2 |
| CONDENSED RING HETEROARYL COMPOUNDS AND USE THEREOF AS TRK INHIBITORS | 2015 |
|
RU2708674C2 |
| COMPOUNDS OF 1-CYANO-PYRROLIDINES AS USP30 INHIBITORS | 2016 |
|
RU2717238C2 |
| NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATION OF CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) | 2015 |
|
RU2684396C2 |
| PYRAZINE COMPOUNDS AND THEIR USE | 2019 |
|
RU2809631C2 |
| PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | 2017 |
|
RU2757457C2 |
| HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | 2017 |
|
RU2742115C2 |
